Dr Hendrik-Tobias Arkenau is the founding Medical Director of the Sarah Cannon Research Institute (SCRI), UK and currently serves as the Executive Medical Director of the Drug Development Program for SCRI UK, leading their UK program of early clinical and tumor specific trials. He is also currently serving as the Clinical Lead for the Hospital Corporation of America International Cancer Service Line.
Dr Arkenau was awarded his medical degree from Hanover Medical School, Germany in 2000, and completed his internship and specialist training in oncology in 2007. Dr Arkenau is Fellow of the Royal College of Physicians, and member of The German Cancer Society, ASCO, AACR and ESMO. He has presented multiple talks on the latest research in oncology and has been an Invited Speaker at several national/international meetings.
Dr Arkenau is a key opinion leader in early oncology clinical drug development, with a special interest in gastrointestinal cancer and melanoma. At SCRI UK, Dr Arkenau has built up a trial portfolio of >80 early clinical trials and is actively involved in protocol development, toxicity review, pharmacokinetic analysis, biomarker and strategic development of new anti-cancer drugs, including immunotherapies.